Monrol

What Monrol does

Monrol, which now operates under the Curium Pharma brand (previously known as Monrol), is a global nuclear medicine and radiopharmaceutical company headquartered with dual global headquarters in Boston, USA and Paris, France. The company develops, manufactures, and distributes a portfolio of more than 50 products spanning generators, hot products, cold kits, and auxiliary supplies used in PET and SPECT imaging as well as targeted radioligand therapy for oncology, cardiology, and neurology applications.

Its core technology base is a vertically integrated radiopharmaceutical manufacturing and distribution network that includes one molybdenum processing facility, 80 manufacturing sites, and more than 45 PET and SPECT nuclear pharmacies serving 70+ countries. Curium operates the full radiopharmaceutical value chain — from isotope processing through to last-mile delivery to hospital nuclear medicine departments — and serves 6,000+ customers worldwide, reaching approximately 14 million patients annually and producing €1bn of revenue in 2025 with a workforce of 3,800+.

The business model is a direct enterprise field-sales motion to hospitals, medical facilities, and nuclear medicine departments, with delivery carried out through company-owned radiopharmacies and manufacturing sites. The company is privately held by CapVest following a November 2025 recapitalization described as the largest transaction in the global nuclear medicine industry, and as of mid-2026 had announced a definitive merger agreement with Lantheus and the acquisition of Abscint SA, both of which would materially reshape its scale and pipeline.

Name

Monrol

Legal name

Curium Pharma

Website

https://monrol.com.tr

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

akta.pro secondary industries

Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI)

Keywords

• Radiopharmaceutical manufacturing
• Nuclear medicine products
• PET imaging agents
• SPECT imaging products
• Radioligand therapy

Headquarters

HQ city

Beykoz

Offices25 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Radiopharmaceutical Products: Sale of nuclear medicine products including generators, cold kits, hot products and auxiliary products used in diagnosis and treatment of diseases

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Monrol (operating as Curium Pharma) is a global nuclear medicine company that develops, manufactures, and distributes radiopharmaceuticals for diagnosis and treatment of cancer, cardiovascular, and neurological diseases. Its product portfolio includes radioactive generators, ready-to-use hot products, cold kits for compounding, PET and SPECT imaging agents, targeted radioligand therapies, and auxiliary products. The company operates the world's largest vertically integrated radiopharmaceutical manufacturing network — spanning one molybdenum-99 processing facility, 80 manufacturing sites, and 45+ radiopharmacies across the US and Europe — delivering time-sensitive radiopharmaceuticals to hospitals and nuclear medicine departments in 70+ countries.

Product overview

Curium Pharma is a global radiopharmaceutical company offering a comprehensive portfolio of nuclear medicine products organized into diagnostic and therapeutic categories. The product portfolio centers on generators (including moly processing), hot products, cold kits, and auxiliary products, spanning PET and SPECT imaging modalities. The company operates the world's largest vertically-integrated manufacturing network in radiopharmaceuticals, with 1 molybdenum processing plant, 80 manufacturing sites, and 45+ radiopharmacies across the globe. Key products include Thallous Chloride TI 201 Injection for cardiac imaging, 64Cu-PSMA-I&T for prostate cancer PET imaging, and targeted radioligand therapies for neuroendocrine tumors and other cancers. The portfolio includes over 50 products distributed across 70+ countries, serving 14 million patients annually.

Differentiator

Problem solved

Functional benefit

Products and services

• Radioactive Generators
• Hot Products
• Cold Kits
• Auxiliary Products
• PET Radiopharmaceuticals
• SPECT Radiopharmaceuticals
• Thallous Chloride TI 201 Injection
• 64Cu-PSMA-I&T
• Targeted Radioligand Therapy (RLT)
• Xenon Xe 133 Gas

Quantifiable outcome

• 14 million patients served annually
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

• Abscint SAcoreStrategic or Co-development Partner · 10 August 2026Curium acquired Abscint SA to expand its PET radiodiagnostic pipeline in oncology. This acquisition strengthens Curium's position in the PET imaging diagnostics market.
• LantheusflagshipStrategic or Co-development Partner · 3 August 2026Curium announced a definitive agreement to merge with Lantheus. This is a major strategic transaction combining two leading radiopharmaceutical companies.
• PeptiDream and PDRadiopharmacoreStrategic or Co-development Partner · 11 June 2026Strategic collaboration for clinical trial of 64Cu-PSMA-I&T for prostate cancer in Japan. Curium Group, PeptiDream and PDRadiopharma announced completion of patient dosing in this clinical trial.
• Neuroendocrine Cancer Awareness Network (NCAN)coreOthersPatient advocacy group providing voice for the NET community by spreading awareness, supporting patients and caregivers, and funding research.
• Learn Advocate Connect Neuroendocrine Tumor Society (LACNETS)coreOthersPatient advocacy organization supporting the NET community through education, advocacy, and patient support.
• International Neuroendocrine Cancer Alliance (INCA)coreOthersGlobal alliance of NET patient advocacy organizations working together to raise awareness and support NET cancer patients.
• The Healing NET FoundationcoreOthersFoundation dedicated to improving care for NET cancer patients through education and awareness.
• NETumor Research Foundation (NETRF)coreOthersNon-profit foundation funding research for neuroendocrine tumor treatments and cures.
• NorCal CarciNETminorOthersRegional NET patient advocacy group serving Northern California.
• Pheo Para AllianceminorOthersPatient advocacy organization for pheochromocytoma and paraganglioma.

Scale indicators10 records

Recent moves9 records

Expansion highlights8 records

Direct peers

• Cardinal Health (Nuclear Pharmacy Services): Operates one of the largest nuclear pharmacy networks in the United States, distributing radiopharmaceuticals to hospitals and clinics. Directly comparable to Curium's US PET and SPECT pharmacy footprint and core radiopharmacy distribution model.
• Lantheus Holdings: Public radiopharmaceutical company specializing in diagnostic imaging agents and radioligand therapies (including PYLARIFY for PSMA PET imaging). Announced definitive merger agreement with Curium in August 2026, making it the most directly comparable peer in both diagnostic and therapeutic nuclear medicine.
• Bracco Imaging: Privately held diagnostic imaging company with a global portfolio of contrast agents and radiopharmaceuticals. Comparable to Curium as a focused imaging-diagnostics peer with overlapping nuclear medicine and hospital customer bases, particularly in Europe.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company focused on PSMA PET imaging (Illuccix) and a growing theranostic pipeline. Directly competes with Curium in PSMA-targeted prostate cancer imaging and represents an emerging pure-play comparable in the theranostic space.

Others

• IBA (Ion Beam Applications): Belgian company specializing in proton therapy, radiopharmacy solutions, and cyclotron-based isotope production. Comparable to Curium as an enabling infrastructure provider for the nuclear medicine ecosystem, supplying equipment and production technology that supports radiopharmaceutical manufacturing.

Broad incumbents

• Siemens Healthineers: Global medical technology incumbent offering imaging systems (PET, SPECT, CT, MRI) and adjacent diagnostic solutions. Comparable as a broad incumbent serving the same hospital and nuclear medicine customers, though primarily through imaging equipment rather than radiopharmaceuticals.
• Novartis (Radioligand Therapy): Major pharmaceutical company with leading radioligand therapy franchise (Pluvicto for PSMA-positive prostate cancer and Lutathera for NETs). Directly competes with Curium in theranostic oncology and sets the commercial benchmark for radioligand therapy adoption and pricing.
• GE HealthCare: Diversified medical imaging and diagnostics incumbent with a significant radiopharmacy and PET tracer business alongside its broader imaging equipment portfolio. Comparable to Curium across the PET/SPECT supply chain and nuclear medicine services, though it competes as part of a much wider healthcare portfolio.
• Philips (Image-Guided Therapy / Molecular Imaging): Diversified health technology company with molecular imaging and image-guided therapy businesses serving hospitals. Comparable as a broad incumbent in clinical imaging workflows that consume radiopharmaceuticals, though it does not directly manufacture nuclear medicine products.
• Bayer (Radiology): Pharmaceutical and life sciences company with an established radiology contrast and radiopharmaceutical business (legacy Xofigo). Comparable as a broad incumbent in imaging diagnostics and radiopharmaceuticals, serving overlapping hospital and nuclear medicine customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCehf34Bp449GjKFowrpyBKg
• LinkedInlinkedin.com/company/curiumpharma
• Instagraminstagram.com/curium_pharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monrol